atenolol has been researched along with Hypertriglyceridemia in 4 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus." | 5.14 | Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. ( Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hall, K; Johnson, JA; Parekh, V; Turner, ST; Wen, S; Zineh, I, 2010) |
| " In the light of the results obtained, the following conclusions were drawn: 1) hyperlipidemia affects pharmacodynamic properties of lipophilic propranolol and hydrophilic atenolol, 2) a modification of the drug dosage in hyperlipidemia is warranted." | 2.71 | [Effect of hyperlipidemia on pharmacodynamics of propranolol and atenolol]. ( Droździk, M; Gawrońska-Szklarz, B; Sterna, R; Sulzyc-Bielicka, V; Telatyńska-Smieszek, B; Wójcicki, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manrique, C | 1 |
| Johnson, M | 1 |
| Sowers, JR | 1 |
| Cooper-DeHoff, RM | 1 |
| Wen, S | 1 |
| Beitelshees, AL | 1 |
| Zineh, I | 1 |
| Gums, JG | 1 |
| Turner, ST | 1 |
| Gong, Y | 1 |
| Hall, K | 1 |
| Parekh, V | 1 |
| Chapman, AB | 1 |
| Boerwinkle, E | 1 |
| Johnson, JA | 1 |
| Telatyńska-Smieszek, B | 1 |
| Wójcicki, J | 1 |
| Droździk, M | 1 |
| Gawrońska-Szklarz, B | 1 |
| Sulzyc-Bielicka, V | 1 |
| Sterna, R | 1 |
| Haitas, B | 1 |
| Disler, LJ | 1 |
| Joffe, BI | 1 |
| Seftel, HC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
2 trials available for atenolol and Hypertriglyceridemia
| Article | Year |
|---|---|
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Drug Therapy, Combina | 2010 |
[Effect of hyperlipidemia on pharmacodynamics of propranolol and atenolol].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Area Under Curve; Atenolol; Blood Pressure; Chrom | 2004 |
2 other studies available for atenolol and Hypertriglyceridemia
| Article | Year |
|---|---|
Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
Topics: Adrenergic beta-Antagonists; Atenolol; Diabetes Mellitus; Diuretics; Drug Therapy, Combination; Fast | 2010 |
Massive hypertriglyceridemia associated with atenolol.
Topics: Adult; Atenolol; Humans; Hypertriglyceridemia; Male; Middle Aged | 1988 |